摘要
Abstract
Objective To analyze the clinical efficacy of interferon α-2 b, low-dose cytarabine and hydroxyurea in the treatment of chronic myelogenous leukemia. Methods Sixty patients with chronic myelogenous leukemia who were admitted from February 2017 to February 2018 were enrolled as subjects. They were randomly divided into observation group and control group, with 30 cases in each group. After admission, the patients were given anti-inflammatory treatment, soda to basalize urine and allopurinol to reduce blood uric acid. The observation group was combined with interferon α-2 b, low-dose cytarabine and hydroxyurea. After treatment, the clinical efficacy, white blood cells, hemoglobin and platelet levels and adverse reactions were compared between the two groups. Results The total effective rate of the observation group after treatment was 93.3％, which was significantly higher than that of the control group.The difference between the two groups was significant (P<0.05). There were no significant differences in the levels of white blood cells (P>0.05), hemoglobin and platelets between the observation group and the control group. After treatment, the levels of white blood cells, hemoglobin and platelets in the observation group were significantly lower than those of the control group. The differences were significant (P<0.05). Conclusion The combination of interferon α-2 b, low-dose cytarabine and hydroxyurea in the treatment of chronic myelogenous leukemia is clinically effective and safe, and it is worthy of widespread promotion and application.关键词
慢性粒细胞白血病/干扰素α-2b/低剂量阿糖胞苷/羟基脲Key words
Chronic myelogenous leukemia/Interferon alpha-2b/Low dose cytarabine/Hydroxyurea分类
医药卫生
